三阴性乳腺癌的治疗与预后标志物研究

Study on Treatment and Prognostic Markers of Triple-Negative Breast Cancer

乳腺癌发病率逐年升高但是死亡率却在下降,然而作为其中异质性较高的三阴性乳腺癌,整体生存率仍差,其治疗方案也在更新换代,目前免疫治疗联合化疗为三阴性乳腺癌提供了新的治疗策略;筛选优势人群使其在免疫治疗联合化疗方案下获益最大是目前最需要攻克的难题,预测疗效的标志物层出不穷,但在肿瘤特异性、亚型的异质性等因素影响下具有局限性。多因素分析寻找合适的预后标志物对于未来三阴性乳腺癌患者治疗方案的选择至关重要,也将是我们后续研究的重点。

The incidence of breast cancer is increasing year by year, but the mortality rate is decreasing. Triple-negative breast cancer as a highly heterogeneous in breast cancer, the overall survival rate is still poor. And its treatment regimen continues to be updated and immunotherapy combined with chemotherapy currently provides a new treatment strategy for TNBC. Screening the suitable population to maximize the benefit under immunotherapy combined with chemotherapy is the most difficult problem to be solved at present. Markers predicting efficacy emerge in endlessly, but have limitations under the influence of factors such as tumor specificity and heterogeneity of subtypes. The search for appropriate prognostic markers by multivariate analysis is essential for the selection of future treatment options for patients with triple-negative breast cancer and will also be the focus of our subsequent study.